

RESULTS OF 2017 ANNUAL GENERAL MEETING

Acrux (ASX: ACR) today held its 2017 Annual General Meeting. In accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* the results of the meeting are set out below and the total number of proxies received are detailed in the attached proxy summary.

Item	Resolution	Outcome
1	Adoption of the Company's Remuneration Report	Not Carried
2	Re-election of Ross Dobinson as a Director	Carried
3	Approval of Omnibus Equity Plan (OEP)	Carried
4	Grant of performance rights to the Chief Executive Officer (CEO) under OEP	Carried

Advisory Resolution 1, Adoption of the Remuneration Report, had more than 25% of proxy votes cast against the Resolution. Accordingly the Board acknowledges this vote and shall consider its position in relation to the remuneration report.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Tim Bateman, CFO and Company Secretary: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au



ANNUAL GENERAL MEETING
Thursday, 26 October, 2017

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 ADOPTION OF REMUNERATION REPORT	7,129,604	8,736,407	561,707	132,545	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
2 RE-ELECTION OF ROSS DOBINSON AS A DIRECTOR	11,315,717	4,531,614	686,724	55,310	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3 APPROVAL OF OMNIBUS EQUITY PLAN (OEP)	9,084,782	5,405,417	1,691,557	378,509	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4 GRANT OF PERFORMANCE RIGHTS TO THE CHIEF EXECUTIVE OFFICER (CEO) UNDER OEP	8,705,789	5,851,842	1,608,142	394,492	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item